Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kymab
Biotech
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
The highest dose of amlitelimab missed the primary endpoint of reducing severe asthma exacerbations at Week 48.
James Waldron
Apr 15, 2025 7:34am
Sanofi cuts staff in Belgium as early-stage research dwindles
Apr 19, 2024 11:34am
Sanofi to shut down UK R&D site, displacing 90 staffers
Mar 13, 2024 10:24am
Sanofi reports setbacks to Denali, Kymab and Principia assets
Oct 27, 2023 6:25am
Sanofi's $1.1B eczema drug hits goal, spurring talk of phase 3
Jun 27, 2023 5:47am
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Jan 11, 2021 7:43am
